Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation

Front Immunol. 2024 Apr 30:15:1381308. doi: 10.3389/fimmu.2024.1381308. eCollection 2024.

Abstract

Chimeric antigen receptor T cells (CAR T) targeting CD7 for T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) showed promising efficacy and safety in some clinical trials. However, most of them were bridged with allogeneic hematopoietic stem cell transplantation (allo-HSCT). We described successful treatment with preventive donor-derived anti-CD7 CAR-T therapy in a case of refractory T lymphoblastic lymphoma following allo-HSCT, who could not receive autologous anti-CD7 CAR-T products due to the low-quality of T lymphocytes. To date, the patient's complete remission has persisted for 20 months after HSCT.

Keywords: CD7 CAR-T; HSCT; T-ALL/LBL; complete remission; preventive infusion.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antigens, CD7* / immunology
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Immunotherapy, Adoptive* / adverse effects
  • Immunotherapy, Adoptive* / methods
  • Male
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Receptors, Chimeric Antigen* / immunology
  • T-Lymphocytes / immunology
  • Tissue Donors
  • Transplantation, Homologous*
  • Treatment Outcome

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.